Forecast Period 
Market Size (Base Year) 
Market Size (Forecast Year)
CAGRGlobal Prescription Digital Therapeutics (PDTx) Market, By Mechanism (Input Mechanisms, Output Mechanisms), Category (Medication Augmentation, Medication Replacement), Treatment (Outpatient Treatment, Monotherapy), Software (Software for Respiratory Conditions, Software for Mental Health, Software for Opioid Use Disorder, Software for Diabetes, Others), Services (Behavioral Microservices, Medical Microservices), App Accessibility (Android, iOS, Windows), App Type (Native Apps, Web Apps), Application (Substance Use Disorder (SUD), Opioid Use Disorder (OUD), Attention Deficit/Hyperactivity Disorder (ADHD), Alzheimer’s Disease, Major Depressive Disorder (MDD), Insomnia, Epilepsy, Movement Disorder, Multiple Sclerosis, Migraine, Autism Spectrum Disorder, Oncology, Inflammation, Respiratory, Cardiovascular, Pain Management, Metabolic Conditions, Others), Patients (Children, Adults) – Industry Trends and Forecast to 2030.
Prescription Digital Therapeutics (PDTx) Market Analysis and Size
The acceptance of PDTx by providers, which in turn depends on payers' willingness to fairly compensate physicians for digital medicines, is key to the success of PDTx. Only 40% of payers were expected to cover PDTx in 2021, according to a Pear Therapeutics and Avalere joint poll, and 50% of them planned to do so in the following 18 months. The main element would be PDTx's clinical effectiveness in enhancing patient outcomes. It is reassuring for PDTx producers as they continue to innovate given the recent flurry of regulatory and FDA approvals for PDTx and the willingness of the majority of payers to fund PDTx reimbursements in the future.
Data Bridge Market Research analyses that the prescription digital therapeutics (PDTx) market which is USD 3.90 billion in 2022, is expected to reach USD 17.16 billion by 2030, at a CAGR of 20.35% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Prescription Digital Therapeutics (PDTx) Market Scope and Segmentation
|
Report Metric |
Details |
|
Forecast Period |
2023 to 2030 |
|
Base Year |
2022 |
|
Historic Years |
2021 (Customizable to 2015 - 2020) |
|
Quantitative Units |
Revenue in USD Million, Volumes in Units, Pricing in USD |
|
Segments Covered |
Mechanism (Input Mechanisms, Output Mechanisms), Category (Medication Augmentation, Medication Replacement), Treatment (Outpatient Treatment, Monotherapy), Software (Software for Respiratory Conditions, Software for Mental Health, Software for Opioid Use Disorder, Software for Diabetes, Others), Services (Behavioral Microservices, Medical Microservices), App Accessibility (Android, iOS, Windows), App Type (Native Apps, Web Apps), Application (Substance Use Disorder (SUD), Opioid Use Disorder (OUD), Attention Deficit/Hyperactivity Disorder (ADHD), Alzheimer’s Disease, Major Depressive Disorder (MDD), Insomnia, Epilepsy, Movement Disorder, Multiple Sclerosis, Migraine, Autism Spectrum Disorder, Oncology, Inflammation, Respiratory, Cardiovascular, Pain Management, Metabolic Conditions, Others), Patients (Children, Adults) |
|
Countries Covered |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
|
Market Players Covered |
ResMed (U.S.), SAMSUNGHEALTHCARE (South Korea), Biofourmis (U.S.), Novartis AG (Switzerland), Medtronic (Ireland), Pear Therapeutics, Inc. (U.S.), Voluntis (France), Omada Health, Inc. (U.S.), GAIA AG (Germany), Welldoc’s Bluestar (U.S.),Solera Network (U.S.), Akili Interactive Labs, Inc. (U.S.), Better Therapeutics, LLC (U.S.), BigHealth (U.S.), Biofourmis (U.S.),Click Therapeutics, Inc. (U.S.), Happify, Inc. (U.S.), Limbix Health, Inc. (U.S.), Naturalcycles Nordic AB (Sweden), NuvoAir AB (Sweden), Sensyne Health plc. (U.K.), Xealth (U.S.) |
|
Market Opportunities |
|
Market Definition
Prescription digital therapeutics is a form of software-based therapeutics used to treat a wide range of illnesses. Technology and biology are combined to make prescription digital medications. These therapeutic tools were created using artificial intelligence, several algorithms, and virtual reality. Prescription PDTs, or digital therapeutics, are a brand-new medicinal category. PDTs act as direct treatments for critical disorders such as conventional biologics or medications.
Prescription Digital Therapeutics (PDTx) Market Dynamics
Drivers
- Rise in the prevalence of chronic diseases will bolster the growth
A significant element influencing the prescription digital therapeutics (PDTx) market's growth rate over the forecast period of 2022–2029 is the rising prevalence of chronic disorders. 463 million persons would develop diabetes in 2020, according to the World Health Organization (WHO). By 2045, it is expected that there will be approximately 629 million diabetics globally.
- Rising uses of DTx will drive the market growth
The healthcare sector's pursuit of value-based care, virtual care and tailored treatment will be accelerated by DTx. By administering interactive, personalized therapy at the patient's leisure, these systems enable providers to provide patient-centric care. This can enhance patient satisfaction, which can enhance treatment adherence and health outcomes while reducing unnecessary administrative burdens on healthcare providers.
Opportunities
- Strong pipeline of potential products is a promising opportunity
Prescription digital therapeutics (PDTx) market growth will benefit from the vast pipeline of prospective products expected to be published over the course of the forecast period. Phase III potential Pear Therapeutics clinical therapeutics products include Pear-011 (anxiety GAD), Pear-015 (depression MDD), which are used to treat adults with chronic insomnia and depression, and CT-152 (major depressive disorder) and CT-155 (schizophrenia), which are used to treat adults with schizophrenia and depression. As a result, it is projected that a number of late-stage medications in development will offer promising opportunities for the growth of the prescription digital therapeutics market.
Restraints/Challenges
- Privacy and security will hinder the market growth
Given the strict regulatory restrictions surrounding PHI (Personal Health Information) data, all parties participating in the manufacture and application of digital medicines must work to protect the confidentiality and security of the information gathered. To protect the privacy of patient data, for instance, manufacturers are required to abide by HIPAA (Health Insurance Portability and Accountability Act) rules. To ensure regulatory compliance of data flows, manufacturers must also cooperate with partners who are HITRUST- (Health Information Trust Alliance) certified. This delays the process which will derail the market growth rate.
This prescription digital therapeutics (PDTx) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the prescription digital therapeutics (PDTx) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In 2020, Reset prescription digital therapies have announced market approval from Singapore's Health Science Authority for the treatment of people with substance use disorders, according to Pear Therapeutics, Inc.
Global Prescription Digital Therapeutics (PDTx) Market Scope
The prescription digital therapeutics (PDTx) market is segmented on the basis of mechanism, category, treatment, software, services, app accessibility, app type, application and patients. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Mechanism
- Input Mechanisms
- Output Mechanisms
Category
- Medication Augmentation
- Medication Replacement
Treatment
- Outpatient Treatment
- Monotherapy
Software
- Software for Respiratory Conditions
- Software for Mental Health
- Software for Opioid Use Disorder
- Software for Diabetes
- Others
Services
- Behavioral Microservices
- Medical Microservices
App Accessibility
- Android
- iOS
- Windows
App Type
- Native Apps
- Web Apps
Application
- Substance Use Disorder (SUD)
- Opioid Use Disorder (OUD)
- Attention Deficit/Hyperactivity Disorder (ADHD)
- Alzheimer’s Disease
- Major Depressive Disorder (MDD)
- Insomnia
- Epilepsy
- Movement Disorder
- Multiple Sclerosis
- Migraine
- Autism Spectrum Disorder
- Oncology
- Inflammation
- Respiratory
- Cardiovascular
- Pain Management
- Metabolic Conditions
- Others
Patients
- Children
- Adults
Prescription Digital Therapeutics (PDTx) Market Regional Analysis/Insights
The prescription digital therapeutics (PDTx) market is analysed and market size insights and trends are provided by country, mechanism, category, treatment, software, services, app accessibility, app type, application and patients as referenced above.
The countries covered in the prescription digital therapeutics (PDTx) market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the prescription digital therapeutics (PDTx) market due to increased research and development being done on prescription digital therapeutics (PDTx) and rising healthcare spending. The expansion of the main companies and the entrance of new start-ups will also accelerate the market's growth rate in this area.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 due to rising healthcare costs and the region's growing prevalence of chronic diseases. Additionally, improvements in the system for paying for digital therapies may speed up the market's expansion in this area.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Prescription Digital Therapeutics (PDTx) Market Share Analysis
The prescription digital therapeutics (PDTx) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to prescription digital therapeutics (PDTx) market.
Some of the major players operating in the prescription digital therapeutics (PDTx) market are:
- ResMed (U.S.)
- SAMSUNGHEALTHCARE (South Korea)
- Biofourmis (US)
- Novartis AG (Switzerland)
- Medtronic (Ireland)
- Pear Therapeutics, Inc. (U.S.)
- Voluntis (France)
- Omada Health, Inc. (U.S.)
- GAIA AG (Germany)
- Welldoc’s Bluestar (U.S.)
- Solera Network (U.S.)
- Akili Interactive Labs, Inc. (U.S.)
- Better Therapeutics, LLC (U.S.)
- BigHealth (U.S.)
- Biofourmis (U.S.)
- Click Therapeutics, Inc. (U.S.)
- Happify, Inc. (U.S.)
- Limbix Health, Inc. (U.S.)
- Naturalcycles Nordic AB (Sweden)
- NuvoAir AB (Sweden)
- Sensyne Health plc. (U.K.)
- Xealth (U.S.)
SKU-
